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Neuromodulation of the immune system has been proposed as a novel therapeutic
strategy for the treatment of inflammatory conditions. We recently demonstrated that
stimulation of near-organ autonomic nerves to the spleen can be harnessed to modulate
the inflammatory response in an anesthetized pig model. The development of
neuromodulation therapy for the clinic requires chronic efficacy and safety testing in a
large animal model. This manuscript describes the effects of longitudinal conscious
splenic nerve neuromodulation in chronically-implanted pigs. Firstly, clinically-relevant
stimulation parameters were refined to efficiently activate the splenic nerve while reducing
changes in cardiovascular parameters. Subsequently, pigs were implanted with a
circumferential cuff electrode around the splenic neurovascular bundle connected to an
implantable pulse generator, using a minimally-invasive laparoscopic procedure.
Tolerability of stimulation was demonstrated in freely-behaving pigs using the refined
stimulation parameters. Longitudinal stimulation significantly reduced circulating tumor
necrosis factor alpha levels induced by systemic endotoxemia. This effect was
accompanied by reduced peripheral monocytopenia as well as a lower systemic
accumulation of CD16+CD14high pro-inflammatory monocytes. Further, lipid mediator
profiling analysis demonstrated an increased concentration of specialized pro-resolving
mediators in peripheral plasma of stimulated animals, with a concomitant reduction of pro-
inflammatory eicosanoids including prostaglandins. Terminal electrophysiological and
physiological measurements and histopathological assessment demonstrated integrity
of the splenic nerves up to 70 days post implantation. These chronic translationalorg March 2021 | Volume 12 | Article 6497861
Sokal et al. Splenic Nerve Neuromodulation Promotes Resolution
Frontiers in Immunology | www.frontiersin.experiments demonstrate that daily splenic nerve neuromodulation, via implanted
electronics and clinically-relevant stimulation parameters, is well tolerated and is able to
prime the immune system toward a less inflammatory, pro-resolving phenotype.Keywords: autonomic nervous system, neuromodulation, stimulation, endotoxemia, specialized pro resolving
mediators, inflammation, bioelectronic medicine, splenic nerveINTRODUCTION
Extensive evidence exists demonstrating that the efferent arm of
the “inflammatory reflex” controls systemic immune responses
via neural circuits that target lymphoid organs, in particular the
spleen (1–3). The spleen is innervated by the splenic nerve (SpN),
which consists of an abundant network of interconnecting fibers
originating from abdominal ganglia (4, 5). This neuronal plexus
runs along the splenic artery (SpA), together forming a
neurovascular bundle (NVB), until it enters the splenic
parenchyma where it releases neurotransmitters, in particular
catecholamines, which subsequently modulate immune cells.
The spleen plays a major role as a reservoir of monocytes/
macrophages and lymphocytes. These cells are activated during
infection and inflammation, resulting in the production of
cytokines and chemokines and in subsequent mobilization
toward sites of inflammation/damage (6, 7).
Exogenous electrical activation of neural pathways targeting the
spleen, either via upstream activation of the cervical vagus nerve
(VN), or near end-organ activation of the SpN, has been shown to
induce cytokine modulation in small animals (2, 8–10). Using acute
inflammatory models, this immunomodulatory effect has typically
been demonstrated as a reduction in cytokine responses, particularly
tumor necrosis factor alpha (TNF-a) (2, 8, 11). This effect has been
shown to be dependent on the SpN, and on noradrenaline (NA)
released from nerve terminals onto splenic leukocytes (8, 11). In
addition, electrical stimulation of such neural pathways has been
shown to reduce inflammation in animal models of arthritis (10, 12,
13) and inflammatory bowel disease (IBD) (14, 15). Importantly,
clinical evidence from feasibility studies of cervical VN stimulation
suggests that neuromodulation of these pathways could be beneficial
in patients with rheumatoid arthritis (RA) (16, 17) and Crohn’s
disease (18). Work from our group and others has provided
evidence that these mechanisms also exist in the pig (4), and
other large animals (15, 19) with gross anatomy, histology,
physiology and immune functions more closely associated to
humans. When compared to small animals, the use of large
animal models is more appropriate to answer questions on
human-relevant clinical device design and therapy translation.
Neuromodulation of the immune system targeting the splenic
circuits represents a new avenue for future treatment of patients
affected by acute and chronic inflammatory conditions. The SpN
represents a suitable target for such an approach, due to its
fundamental role in regulating immunological responses as well
as its proximity to the target organ, allowing direct splenic activation
while potentially avoiding some off-target effects seen with more
indirect distal intervention sites of the autonomic nervous system.
We have shown that the pig represents a suitable pre-clinical modelorg 2to investigate and refine neuromodulation therapies targeting the
SpN (4). Acute activation of the SpN, using human-relevant
stimulation parameters, reduces production of TNF-a and IL-6
following endotoxemia in terminally-anesthetized pigs. In addition,
we demonstrated that SpN stimulation (SpNS) caused amplitude-
and frequency-dependent changes in SpA blood flow (BF) and
systemic mean arterial blood pressure (mABP), which are directly
correlated to nerve activation. These acute systemic physiological
biomarkers provide a surrogate of target engagement and can be
used to determine nerve activation and allow the refinement of
neuromodulation parameters. Based on these findings, the
feasibility and safety of acute SpN neuromodulation, during
minimal ly- invas ive surgery for esophagea l cancer
(esophagectomy), is currently being evaluated to assess impact on
inflammatory and physiological responses (clinicaltrials.gov
Identifier: NCT04171011).
The translation from an acute model to a potential chronic
therapeutic modality however requires further elucidation. Given
the differences between small rodent and human models, conscious
large-animal studies investigating the effects of long-term nerve
stimulation are a fundamental step toward clinical translation (20).
They are needed to refine tolerable and efficacious stimulation
parameters, provide evaluation of safety and long-term integration
of the system, and develop understanding of long-term
neuromodulation on physiological functions. This is particularly
crucial for immunomodulatory therapies, since general anesthesia is
known to affect immunological functions (21). In addition, large
animal models can reveal biological effects previously not studied in
rodent models. For example, it has been demonstrated by our group
and others, that SpN or VN neuromodulation promotes
cardiovascular protection in endotoxemia models in pigs via a
mechanism independent of cytokine modulation (4, 22), suggestive
of regulation of additional pathways beyond cytokine production.
It has been shown that the autonomic nervous system may
regulate dynamic mechanisms associated with leukocyte
recruitment and resolution processes during inflammation (23,
24), with neurotransmitters and the spleen possibly playing a
central role. Resolution of inflammation is an active process
requiring fine regulation of biosynthetic pathways that lead to
the production of lipid mediators, called specialized pro-
resolving mediators (SPMs) (25). SPMs play a central role in
reprogramming both innate and adaptive immune responses to
regulate immune cell recruitment and cytokine production. Loss
of vagal signaling leads to a disruption in SPM biosynthesis and
disrupted resolution mechanisms (23, 24). Therefore, it is
possible that the same neural circuits that modulate cytokine
responses could affect the regulation of SPMs to promote
inflammation resolution, potentially broadening the field ofMarch 2021 | Volume 12 | Article 649786
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inflammatory disorders.
Herein we describe the refinement of stimulation parameters
suitable to achieve effective SpN activation and neurotransmitter
release, with reduced off-target effects in terminally-anesthetized
pigs. Subsequently, pigs were implanted using a novel, minimally-
invasive laparoscopic surgical procedure to place a circumferential
cuff electrode interface around the splenic NVB, connected to a
subcutaneous implantable pulse generator (IPG) to enable the
delivery of chronic neuromodulation. Following recovery from
surgery, the tolerability of electrical stimulation of the SpN was
then evaluated in these conscious, freely-behaving pigs.
Subsequently, multiple immunological parameters were quantified
in both naïve and endotoxin-challenged inflammatory conditions.
Specifically, cytokine production, cell phenotypic changes and SPMs
were analyzed in peripheral blood prior to, and after a systemic
immune challenge with lipopolysaccharide (LPS), comparing SpN
stimulated and non-stimulated “sham” animals. Finally, terminal
contrast angiography, electrophysiology and histopathology were
performed to evaluate the integrity of the splenic NVB after
chronic implantation.MATERIALS AND METHODS
All animal studies were ethically reviewed and carried out in
accordance with Animals (Scientific Procedures) Act 1986. The
protocol was approved by the Royal Veterinary College Animal
Welfare and Ethical Review Board and the Galvani
Bioelectronics Animal and Scientific Review Committee. All
animals were transported and housed under conditions
specified in the United Kingdom Animal Welfare Act 2006
and The Welfare of Farm Animals (England) Regulations 2007.
Stimulation Parameters
Stimulation parameters and paradigms used are described in the
relevant sections in the methods and results and are summarized
in Supplementary Table S5 and Supplementary Figure S13.
Acute Terminal Study Methods
Additional details are described in Supplementary Methods.
Refinement of SpNS Parameters – Electrophysiology
Animals
5 female farm pigs (Large white pigs; body weight 45 – 50 kg, age
10 – 12 weeks) were sourced from a commercial pig farm. On the
day of the experiment, anesthesia induction was performed as
described for chronic conscious animals below.
Surgery
Commencing at the origin of the SpA, a 10 mm long segment of the
artery with an intact periarterial SpN plexus was carefully separated
from the splenic vein (SpV) and surrounding connective tissue.
Electrophysiology
The NVB was subsequently instrumented with a bipolar
circumferential cuff electrode (see Supplementary Methods).Frontiers in Immunology | www.frontiersin.org 3A distal discrete SpN fascicle was carefully isolated and
subsequently instrumented with a bipolar cuff electrode (see
Supplementary Methods) to record evoked compound action
potentials (eCAP). For monitoring blood flow changes during SpNS,
an ultrasonic transit timeflowprobe (Transonics, USA)was placed on
the SpA immediately proximal to the electrodes. Electrophysiological
and physiological parameters were recorded as detailed in
Supplementary Methods. The splenic NVB was stimulated via the
periarterial cuff electrode (described in Supplementary Table S1).
eCAPs and physiological parameters were subsequently recorded and
quantified as described in Supplementary Methods.
Refinement of SpNS Parameters -
Noradrenaline Output
Animals
5 female farm pigs (Large white pigs; body weight ~70 kg, age ~5
months) were used; animal sourcing, management and
anesthesia protocols were as described above.
Surgery
Anesthesia, placement of bilateral jugular venous catheters and a
femoral arterial catheter and monitoring and recording of all
parameters were performed as described above. Open
laparoscopic surgery and isolation of the splenic NVB followed by
cuff electrode and flow probe placement was performed as above.
After probe placement, a cannula (12G, 3.25”; Angiocath, BD,
UK) was inserted such that its tip lay within the common SpV.
The base of the spleen was reintroduced into the abdomen.
Stimulation and Blood Sampling
The effects of SpN stimulation on blood flow and NA
concentration in the SpV were tested at 6 stimulation intensities,
inclusive of sham. Summary of stimulation parameters are shown
in Supplementary Table S5. The different stimulation intensities
were delivered to each animal in a randomized order, using a
truncated 6x6 randomly-generated Latin Square design.
Blood was sampled before and during SpNS as described in
Supplementary Methods. Following each stimulation intensity,
a period of 60 mins was allowed for the preparation to re-
stabilize before performing the next stimulation. Physiological
parameters and blood flows were continuously captured using
the Powerlab system (AD Instruments). Following the final
stimulation and sampling period, the animal was euthanized
by injection of pentobarbital.
NA Analysis
Frozen plasma aliquots were analyzed and quantified as
described in Supplementary Methods.
Chronic Conscious Neuromodulation
Study Methods
The overall study design is outlined in Figure 3A and is
described in more detail in Supplementary Methods.
Animals
A total of 12 female Berkshire pigs (74-99 kg at start of study; ~9
months old) were used for the chronic implant study. Female
pigs were used due to their temperament and smaller size. TheMarch 2021 | Volume 12 | Article 649786
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the research facility and underwent handling and socialization
training for a minimum of 1 month prior to the experiment.
Neuromodulation Device
The stimulation lead and implantable pulse generator (IPG) are
described in the Supplementary Methods.
Surgery
Implantation of the Neuromodulation Device
Animals were anesthetized and underwent minimally invasive
laparoscopic surgery via a left sided lateral approach (Figures
3B, C). Following retraction of the stomach and then spleen, the
splenic NVB was dissected free from the surrounding tissue and
the circumferential cuff electrode was implanted around
the SpNVB.
Stimulation applied with an external pulse generator (EPG
(DS5, Digitimer, UK)) confirmed electrical integrity of the
implanted stimulation lead and physiological functionality by a
measured increase in systemic mABP. The IPG was implanted in
a subcutaneous pocket on the dorso-lateral thorax and the lead
tunneled to connect to the IPG before surgical closure of
all incisions.
Intra-Operative Neuromodulation of the SpN (at Surgery
and at Termination)
At implantation, neuromodulation was delivered at either 15 or
40 µC using a 10 Hz continuous paradigm to confirm target
engagement (see Supplementary Methods). Electrode
impedance was measured throughout the course of the study.
At termination, stimulation was delivered using either the
10 Hz continuous or burst paradigm with an EPG up to 40 µC
with measurement and assessment of SpA BF and mABP as
described above.
Vascular Access Port Implantation
All animals were subsequently implanted with an intravenous
catheter in the left external jugular vein, using a minimally-
invasive ultrasound-guided approach, which was terminated with
a subcutaneous vascular access port (Supplementary Methods) to
enable repeated, stress free, blood sampling in conscious animals.
Recovery
Animals were routinely recovered from anesthesia and returned
to their pens. Recovery was assessed by return to normal
behaviors, pain scoring, wound healing, and body weight.
Determination of Effects of Chronic
SpN Neuromodulation
Tolerability to SpNS as Determined by
Behavioral Responses
Animals were given a 14 day recovery period following surgery after
which only those assigned to the neuromodulation group (n=6)
were stimulated at either 15 or 40 µC using the 10 Hz burst
paradigm. Stimulation was tested at ascending 1 mA (2 µC)
intervals. For each stimulation current amplitude, stimulation was
ramped-up over 30 s and then held for a further 60 s (90 s total).Frontiers in Immunology | www.frontiersin.org 4During neuromodulation, animals were observed by two
independent trained assessors for any responses indicative of
perception of stimulation (scoring system and observed
responses are described in Supplementary Methods).
Baseline Blood Testing
Animals were then maintained for a further 14 day period
without stimulation, after which time all animals underwent
baseline blood sampling taken from the VAP for hematology,
clinical biochemistry, ex vivo LPS cytokine assays and flow
cytometry (only performed in cohorts 3 and 4), nominally at
day -2, -1 and 0, at the same time of day (around 10:00 h) (see
Figure 3A for overall study design).
Biomarker Assays in Naïve animals
To determine the effects of SpNS in naïve animals, chronic
neuromodulation therapy (10 Hz burst at IPG output of either
15 or 40 µC, 7 days a week (see Supplementary Table S5 for
stimulation parameters)) was initiated from Day 0, following the
base l ine tes t ing . Cohorts 1 and 2 (n=6) rece ived
neuromodulation 6 times per day from 09:00 at 90 min
intervals, while in cohorts 3 and 4 (n=6), neuromodulation was
performed 12 times per day from 07:00 at 60 min intervals.
Animals assigned to the sham group (n=6) were not stimulated.
On Days 2 and 7, scheduled neuromodulation was stopped
after the 09:00 stimulation and blood drawn from all animals
around 10:00 for ex vivo LPS cytokine assays (plus, additional
samples per baseline bloods as described above). Scheduled
neuromodulation was then restarted so the animals received
their 11:00 therapy session.
Ex vivo LPS Cytokine Assays. Duplicate samples of peripheral
sodium heparinized venous blood (collected via the VAP) were
immediately incubated with either 0, 100 or 1000 ng/mL LPS for
four hours (see Supplementary Methods for further details).
Samples were then centrifuged at 2000 xG and the supernatant
stored at -80°C and TNF-a analyzed as described in
Supplementary Methods.
Flow Cytometry. Sodium heparin vacutainers were filled with
10 mL blood collected from the VAP and kept at 4°C until
processing (which occurred within 2 h from collection). Blood
was treated with red blood cell lysis buffer (ammonium chloride
lysis buffer), then centrifuged at 2000 xG and washed twice in
cold PBS. Cells were transferred to individual FACS tubes con-
taining 900 µL FACSFlow™ buffer (342003, Becton, Dickinson
UK Ltd., Wokingham, UK).
Cells were then stained for CD4/CD8, CD16/CD14 and
CD172a/CD163 using dye-conjugated antibodies. Isotype
matched controls were used. All antibodies are listed in
Supplementary Table S6. The samples were analyzed on a BD
FACSCalibur™ (Becton, Dickinson) and 10000 events acquired
using BD CellQuest Pro™ software. Details of gating strategy are
reported in the Supplementary Materials.
Hematology and Biochemistry. Samples for hematology and bio-
chemistry analyses were submitted to a commercial laboratory. Full
details of analytes measured are shown in Supplementary Table S2.March 2021 | Volume 12 | Article 649786
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Neuromodulation was continued following the naïve assessment
described above and the next day in vivo LPS testing was
performed. Sham animals were maintained for a matching
time period. One sham animal was excluded from the in vivo
LPS part of the study on veterinary recommendation for reasons
not associated with the study.
In Vivo LPS and cytokines assay. Baseline blood was drawn
from all animals at time 0 h and they were subsequently injected
with LPS (0.025 µg/kg i.v. over 5 mins; E. coli as above; see
Supplementary Methods for LPS preparation). This dose of LPS
was chosen based on previous work in this group (4) and from a
pilot study as outlined below. Following LPS injection, bloods
were drawn throughout the day for cytokine analysis, hematol-
ogy, biochemistry, flow cytometry and Specialized Pro-Resolvin
Mediator analysis (see Supplementary Methods).
LPS injection was coordinated such that stimulation animals
(n=6) received scheduled neuromodulation immediately before
LPS injection, followed by an additional manual stimulation five
minutes post-injection.
For cytokine analysis, venous blood samples collected in
EDTA tubes were immediately centrifuged at 2000 xG for 5
mins at 4°C. Plasma was then separated and immediately frozen
on dry ice and subsequently stored at –80°C. These plasma
samples were used to measure TNF-a concentration using the
commercial ly available ELISA kits described above
(R&D systems).
All other blood analyses were run as described above.
Targeted Lipid Mediator Profiling. Specialized Pro-Resolving
Mediator analysis was performed on plasma samples taken as
above during the endotoxemic phase in this conscious study.
Additionally, similar analysis was performed on plasma samples
collected during a low dose anesthetized endotoxemia study with
acute SpNS (4) at 0, 0.5 and 2 h post LPS administration.
Plasma lipid mediators were extracted using solid-phase extraction
columns as described in (26) and Supplementary Methods.
Data Analysis
TNF-a, hematology bloodwork and flow cytometry data were
analyzed in InVivoStat 4.0 (see https://invivostat.co.uk/) and
visualized in Graphpad Prism 8.4.2.
TNF-a Data Analysis: Ex Vivo LPS Assay
The ex vivo TNF-a data were analyzed for each LPS
concentration using a 2-way repeated measures mixed model
approach, with neuromodulation as the treatment factor,
timepoint (average of baseline, +2 and +7 days) as the repeated
factor, and cohort as the blocking factor. The responses were
log10 transformed prior to analysis to stabilize the variance.
Planned comparisons were then made at each timepoint, and
the unadjusted p-values were corrected using Hochberg’s
multiple comparison procedure.
TNF-a Data Analysis: In Vivo LPS Assay
The area under the curve (AUC) was calculated for plasma TNF-
a between 0.5 and 2.0 h post-LPS injection (AUC0.5- 2.0) for eachFrontiers in Immunology | www.frontiersin.org 5animal individually; the time period during which the majority of
the TNF-a increase, peak and subsequent decline occurred.
Baseline for AUC for each animal was taken as the value of its
baseline TNF-a prior to LPS injection. Data were analyzed using
a 1-way ANCOVA approach, with neuromodulation or no
neuromodulation as the treatment factor and baseline TNF-a
(prior to LPS injection) as the covariate. The responses (AUC
and baseline TNF-a) were log10 transformed prior to analysis to
stabilize the variance. The cohort was included as a blocking
factor to account for day-to-day variability.
Hematology and Biochemistry
The data were analyzed using a 2-way repeated measures mixed
model approach, with neuromodulation as the treatment factor,
timepoint (average of baseline, +2 and +7 days or 0-24 h for
naïve and endotoxemia phases respectively) as the repeated
factor, cohort as the blocking factor and baseline cell count as
the covariate. The responses and covariate were log10
transformed prior to analysis to stabilize the variance. Planned
comparisons were then made at each timepoint, and the
unadjusted p-values were corrected using Hochberg’s multiple
comparison procedure.
Flow Cytometry
The data were analyzed as per the hematology and biochemistry
but without a covariate or transformation. Data were expressed
as % change over the baseline value. Baseline value for the naïve
phase was defined as the average value across the 3 days (–2, –1,
0) prior to initiation of stimulation. For the endotoxemia phase
the baseline was defined as time 0 h prior to LPS challenge.
Lipid Mediators
Lipid mediators were analyzed by multivariate analysis
performed using online open access metaboloanalyst (https://
www.metaboanalyst.ca/MetaboAnalyst/home.xhtml) using
statistical analysis tool. Features with a constant or single value
across samples were deleted. Partial Least Square Discriminant
Analysis was then performed following auto-scaling (mean-
centered and divided by the standard deviation of each
variable). Network analyses was performed on normalized
concentrations (expressed as the fold change) of the lipid
mediators from the Sham and SpNS groups and lipid mediator
biosynthetic networks were constructed using Cytoscape 3.7.1.
Terminally-Anesthetized Procedures
Following in vivo LPS testing, 10 of 12 animals were terminally
anesthetized for contrast angiography, SpNS and gross and
histological pathology analysis. Two animals were excluded
from terminal studies for use in further work (not described in
this paper). Following anesthesia contrast angiography was used
to show retention and alignment of the lead electrode around the
splenic artery (see Supplementary Information).
Open laparotomy surgery (as described above) was
performed in all animals and splenic neuromodulation
performed with the IPG and an EPG. Sham animals did not
undergo terminal stimulation in order to preserve their status as
sham animals to provide samples for studies not described in this
paper. Thresholds and stimulation response curves for changesMarch 2021 | Volume 12 | Article 649786
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described in Supplementary Table S5 and methods as described
above for intraoperative stimulation. The relationship between
these thresholds and cytokine response in the in vivo TNF-a
assay were determined within-animal.
Following measurement of BP and BF, a small SpN fascicle
was dissected free from the NVB, more distal to the implanted
lead cuff. eCAP recordings were in all animals to provide
additional electrophysiological evidence of functional
SpN fascicles.
Following euthanasia the following areas were grossly
examined in detail: the abdominal wall and abdominal cavity
immediately surrounding the implantation site (including the
pancreas, spleen and liver); the IPG location and the cuff
electrode location. Following gross pathology examination,
tissues were harvested and processed for histopathology and
assessed as described in the Supplementary Methods and
Supplementary Table S7.
Pilot Study Investigating LPS Dose in
Non-Surgical Sham Animals
A pilot study was performed in 4 Berkshire pigs (sex, age and size
matched to above study) to inform the LPS dose for the in vivo
challenge in this paper. Additionally, they provided a group of
non-surgical sham animals for comparison to animals implanted
with electrodes and IPGs in the main study. Briefly, animals were
anesthetized, a VAP implanted and then recovered (as described
previously). In vivo LPS and cytokine assays were performed (as
above) to assess the effect of two LPS dosages: 0.0025 µg/kg i.v.
and 0.025 µg/kg i.v. The dose of 0.0025 µg/kg did not evoke TNF-
a release (data not shown) unlike the 0.025 µg/kg dose which
provided a robust, consistent cytokine response in the absence of
any clinically adverse effects on the animals. On this basis, the
0.025 µg/kg dosage was selected for the main study.RESULTS
Refinement of Stimulation Parameters
Therapeutic SpNS should be delivered in such a way that it
maintains action potential transmission and achieves continued
neurotransmitter (i.e., NA) release at the terminals while
minimizing local vascular effects on the splenic smooth muscle
and systemic circulation. Therefore, stimulation parameters were
initially refined by measuring evoked compound action
potentials (eCAPs) and physiological parameters during SpNS
in terminally-anesthetized pigs.
There was a frequency-dependent effect of stimulation on
SpN conduction velocity and eCAP amplitude. When
stimulating at 1 Hz, conduction velocity was calculated as
0.84 m/s (range: 0.39 to 1.59 m/s) in line with previous data
(4) and e.g (27). Continuous stimulation at frequencies greater
than 1 Hz resulted in marked action potential conduction
velocity slowing, as measured by increased eCAP latency; this
phenomenon was evident when stimulating at 10 or 30 HzFrontiers in Immunology | www.frontiersin.org 6(Figures 1A, B). In parallel, continuous stimulation at these
frequencies showed a concomitant reduction of the eCAP
amplitude (Figures 1A, C). These phenomena were almost
completely prevented by stimulating at 1 Hz or by applying
bursts of stimulation at 10 Hz (repeated bursts of 5 pulses at
10 Hz, 0.5 s on and 4.5 s off). During stimulation with either of
these paradigms over 600 stimulation pulses, reduction of the
eCAP amplitude and conduction velocity was avoided (Figures
1A–C). Furthermore, when stimulating with the 10 Hz burst
paradigm, the conduction velocity and the eCAP amplitude
actually increased between the 1st and the 10th pulse of a
10 Hz stimulus train, peaking after 4-6 pulses (Figure 1D).
These initial augmentative effects were absent when using 1 or
30 Hz stimulation.
Our group has previously shown that SpNS delivered at 10 Hz
induces changes in SpA BF and systemic mABP that are directly
related to activation of efferent (toward the spleen) SpN axons
(4). The effects of stimulation using either a 1 Hz continuous or
10 Hz burst paradigm were significantly lower (approximately
50% reduction) on both local (SpA BF) and systemic (mABP)
physiological parameters, compared to 10 Hz continuous
stimulation (P ≤ 0.01; Figures 2A, B). There was no difference
in effect between stimulation using 1 Hz continuous or
10 Hz burst.
Taken together these data suggest that 10 Hz burst
stimulation may be a more refined stimulation pattern for
sustained SpN neuromodulation in the presence of reduced
cardiovascular effects.
The anti-inflammatory effect of autonomic neuromodulation
has been shown to be dependent on the SpN, and on NA released
from nerve terminals onto splenic leukocytes (4, 8, 11).
Therefore, to evaluate the potential efficacy profile of burst
stimulation, the concentration of NA was used as a pathway-
and mechanism-relevant biomarker. Continuous or burst
stimulation at 10 Hz were applied at different stimulation
intensities while the output of NA from the spleen into the
SpV was measured, alongside SpA BF and mABP. Stimulation
with either paradigm evoked an intensity- and frequency-
dependent release of NA (Figure 2C) which was maintained
during 120 s of stimulation. Stimulation of the SpN with the
burst paradigm resulted in reduced cardiovascular effects with an
apparent reduction in total NA secretion when compared to
10 Hz continuous delivered at the same stimulation charge
(1.70 ± 0.39 versus 3.76 ± 0.98 µM.s, a reduction of 45.2%;
P=0.08, Figure 2D). However, when normalized over the total
number of pulses delivered, burst stimulation released a
significantly higher amount of NA per stimulation pulse
(P=0.010; Figure 2E).
Taken together, these findings suggest that burst stimulation
(10 Hz; 0.5 s on; 4.5 s off) is an efficient stimulation paradigm;
able to evoke maintained SpN activation and NA release, in the
presence of reduced effects on the SpA BF and mABP. Given that
120 s of 10 Hz continuous stimulation has been shown to be
immunomodulatory in acute studies (4), it was hypothesized that
burst stimulation for 4.5 mins (1/45.2% or 2.21 times longer)
would result in significant immunomodulation. This paradigmMarch 2021 | Volume 12 | Article 649786
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implanted animals.
Chronic Splenic Nerve Neuromodulation
Chronic Implantation and Intraoperative Stimulation
The overall chronic study outline is shown in Figure 3A. A total of
twelve female pigs underwent a novel minimally-invasive
laparoscopic surgical procedure (Figures 3B, C). This implantation
procedure was refined through studies in both human and pig
cadavers with input from human and veterinary surgeons. The
splenic NVB was surgically isolated from surrounding tissue, and a
circumferential cuff electrode was implanted around the artery and
nerve plexus. The electrode lead then exited the abdomen where it
was connected to a subcutaneously-located implantable pulse
generator (IPG). A catheter was placed in the jugular vein and
connected to a subcutaneously-implanted vascular access port to
enable serial blood sampling.
During laparoscopic implantation of the stimulation lead and
IPG, SpN neuromodulation with a 10 Hz continuous paradigm
(60 s) was used to confirm both placement and function of the
implanted lead, IPG and target engagement, as performed in the
on-going clinical trial described previously. Animals wereFrontiers in Immunology | www.frontiersin.org 7stimulated at their respective IPG charge outputs (see methods
for details) of 15 µC or 40 µC. Stimulation evoked an increase in
mABP of 9.81 ± 6.83% (n=5) at 15 µC or 10.31 ± 5.87% (n=7) at
40 µC (Supplementary Figure S1). In all animals the increase in
mABP was temporally-correlated to the onset and offset of
stimulation, in line with the acute experiments described
above, and was used as confirmation of target engagement and
functionality of the implanted SpN neuromodulation system
prior to animal recovery.
Following implantation surgery, all animals recovered well
without complications. Electrodes were monitored throughout
the course of the study to assess continued function of the IPG
and stimulation lead integrity.
Following implantation, impedance was 404.33 ± 62.68 W
(n=10 of 12), and peaked around 11 days post-implantation
(583.21 ± 89.78 W) before plateauing around 540 W for the
remainder of the study (Supplementary Figure S2).
Given the practical limitations of chronically-implanted
large-animal studies and associated biomarker assays, animals
proceeded through the study in four cohorts, with each cohort
consisting of animals receiving chronic SpN neuromodulation,
and sham animals implanted with an identical stimulation leadA
B C D
FIGURE 1 | Burst Stimulation (10 Hz; 0.5s on 4.5s off) Sustains SpN Activation. (A) Representative SpN eCAPs obtained when stimulating the SpN at 1, 10, 30 Hz
or 10 Hz burst (5 pulses delivered at 10 Hz, with a 4.5 s delay between bursts). Each image shows 300 consecutive pulses overlapped. The stimulation artefact was
removed for clarity. The dashed lines indicate the latency of the peak of the first (white line) and last (red line) recorded eCAP. The arrows indicate the amplitude of
the peak of the first (white arrow) and last (red arrow) recorded eCAP. (B) Quantified eCAP amplitude (expressed as percentage of the max response) over 600
consecutive pulses with the different pattern of stimulations shown. Data are shown as mean (n = 3). Least-squares regression curves were fitted against the data.
(C) Quantified eCAP latency (expressed as percentage of the first response) over 600 consecutive pulses with the different pattern of stimulations shown in (A). Data
are shown as mean (n = 3). Least-squares regression curves were fitted against the latency data. (D) eCAP amplitude (expressed as percentage of the first
response) over the first 5-10 pulses with the different pattern of stimulations.March 2021 | Volume 12 | Article 649786
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mechanical failure of the electrode was noted in two animals
prior to onset of chronic neuromodulation. Given that electrode
failure was not caused by animal- or nerve-related issues, these
animals were assigned to the sham group. Other animals were
randomly assigned to either the SpNS or sham group.
Effects of Chronic Neuromodulation in Naïve Animals
To assess behavioral tolerability of SpN neuromodulation,
approximately 14 days following device implantation, SpNS pigs
were stimulated using the 10 Hz burst paradigm using a step-up
protocol between 1 and 15 or 40 µC (in increments of 1-2 µC). The
behavioral responses to stimulation were not assessed in shamFrontiers in Immunology | www.frontiersin.org 8animals. There was no evidence of behaviors or responses indicative
of perception of neuromodulation of the SpN in any animal at any
of the stimulation amplitudes used. Animals were then maintained
without stimulation until approximately 28 days following
device implantation.
The effects of chronic SpNneuromodulationwere then assessed
to examine any potential immunosuppressive effects in animals
naïve to inflammatory challenge. Thiswas performedbymeasuring
ex vivo peripheral whole blood LPS-induced TNF-a production,
hematological and clinical biochemistry measurements and flow
cytometry. Baseline peripheral blood samples were collected from
all the animals prior to initiation of chronic neuromodulation,
nominally days -2, -1 and Day 0.A B
C D E
FIGURE 2 | Burst Stimulation (10 Hz; 0.5s on 4.5s off) Sustains NA Release While Reducing Cardiovascular Effects. (A) Changes in SpA BF and mABP during a 60
s stimulation of the SpN using a 5 µC stimulus delivered at 10 Hz, 1 Hz or 10 Hz burst stimulation. Data are from stimulations within the same representative animal
(shown as empty circles in 2B). (B) Relative SpA BF and mABP changes recorded during a 60 s stimulation delivered with stimulation at 1 or 10 Hz continuous or
10 Hz burst. Values are expressed as percentage of the average maximum change obtained at 10 Hz continuous across all animals. Individual data points are
shown (at least 2 replicates from each animal) and mean (n = 4) + s.d. * represent significant statistical difference from 10 Hz continuous. (C) Graph showing the
concentration of NA at each time point during baseline and stimulation periods (2 min) at different amplitude (0-11 µC) or pattern (continuous or burst at 10Hz) as
indicated. Data are shown as mean (n = 5) + s.e.m. (D, E) Graph showing the comparison of NA release during stimulation at 10 Hz continuous or 10 Hz burst at
the same stimulation intensity, expressed as AUC (D) or as AUC normalized over the total number of pulses (E) delivered during the 120 s period of stimulation
(1200 vs 120, respectively). Statistical analysis was performed using One-way ANOVA and Tukey post-hoc correction for multiple comparison. *P ≤ 0.05; **P ≤ 0.01;
***P ≤ 0.001; ****P ≤ 0.0001. or individual P-values are shown.March 2021 | Volume 12 | Article 649786
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days at either 15 or 40 µC using the 10 Hz burst paradigm (5mins/
session; 12x/day; full parameters described in the methods) and
further blood samples were collected on Days 2 and 7. There was a
clear concentration-response relationship between LPS and the
amount of TNF-a measured in the plasma isolated from
whole blood incubated ex vivo with varying concentrations of
endotoxin (Supplementary Figures S3A–C). Considering the
neuromodulation period between day 0 and 7, there was no
difference in TNF-a release between SpNS and sham animals.
Additionally, there was no effect of SpNS on total white blood
cell, neutrophil or monocyte counts (Figures S3D–F respectively),
or any other hematological or clinical biochemistry parameters
(Table S1), comparing either within the SpNS animal groups
between baseline and Day 2 or Day 7, or between SpNS and sham
animals on Day 2 or Day 7.
To further evaluate effects on the immune system in animals
naïve to inflammatory challenge, peripheral blood leukocytes were
stainedwith antibody against the surfacemoleculesCD14/CD16, or
CD172a/CD163, or CD4/CD8, to identify potential changes inFrontiers in Immunology | www.frontiersin.org 9major leukocyte subsets by flow cytometry. As expected CD14,
CD16 and CD172amarkers were expressed not only bymonocytes
but also by lymphocytes and granulocytes. Plotting these markers
against side scatter allowed us to distinguish between these three
populations and therefore to specifically quantify monocytes (see
Supplementary Figures S4, 5; and Methods for details).
Subsequent analysis did not reveal any significant effect of SpNS
within or between groups when quantifying the proportion of
monocytes that were CD16+ (Supplementary Figures S3G, H),
CD172a+ (Figure S3I, J), CD14+ (Figure S6D) or CD163+
(Supplementary Figure S6E). No significant differences were
observed when quantifying the expression (as median
fluorescence intensity; MFI) of CD14 on CD16+ monocytes
(Supplementary Figures S3K, L). Furthermore, no changes were
noted in theT cell compartment (Supplementary Figures S6A–C).
Effects of Chronic Neuromodulation During
In Vivo Endotoxemia
Following evaluation of the effects of SpNS in naïve animals, the
effects of neuromodulation were assessed in an in vivoA
B C
FIGURE 3 | Chronic Conscious Neuromodulation Study Methods and Refinement of the Minimally-Invasive Surgical Implantation Procedure. (A) Schematic of overall
chronic conscious study design. Each phase is described in more detail in the methods and supplementary information. (B) Schematic of surgical implantation
procedure showing trocar position and use, relative to the spleen. (C) Schematic of chronic neuromodulation and blood sampling procedure. Animals were
implanted with a catheter in the jugular vein and a circumferential cuff electrode around the splenic neurovascular bundle (NVB) connected to an implantable pulse
generator (IPG). The IPG was wirelessly controlled by a tablet to control stimulation parameters and measure impedance.March 2021 | Volume 12 | Article 649786
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day (day 8) following which animals were subjected to low dose
endotoxemia by systemic injection of LPS via the jugular vein
catheter. Peripheral blood was collected to quantify LPS-induced
plasma TNF-a and SPM concentrations in peripheral plasma, and
hematological and clinical biochemistry parameters.
The dose of LPS used in the current study was validated in a
preliminary cohort of animals implanted only with the vascular
access catheter (n=4; non-surgical (NS) sham), and was initially
selected based on experience with anesthetized LPS experiments
(4) and evidence in literature. The dose selected (0.025 µg/kg,
i.v.) was shown to evoke a robust increase in plasma TNF-a
levels (Figure 4A; grey trace) in the presence of only mild to
moderate clinical behaviors (see Methods).
Following systemic injection of LPS, typical clinical behaviors
(lethargy and shivering) were seen in all animals; these started
around45minpost-injectionandpersisted for around45min in theFrontiers in Immunology | www.frontiersin.org 10case of shivering and 4 h for the lethargy. These behaviors resolved
without the need for medical intervention. In all pigs, LPS injection
caused an upregulation of systemic TNF-a levels (Figure 4A)
peaking at 1 h post injection. However, this dynamic
upregulation of TNF-a was smaller in SpNS animals in
comparison to sham as well as NS sham animals. Quantification
of the total amount of TNF-a, measured as area under the curve
(AUC) between 0.5 and 2.0 h post-LPS injection (the time period
including TNF-a increase, peak and subsequent decline occurred),
revealed a significant reduction of TNF-a in SpNS vs shamanimals
(Figure4B); therewas a reductionof approximately40% inSpNSvs
sham animals (P=0.029; 345.0 ± 42.62 vs 566.0 ± 213.0 pg/ml.h,
respectively). The amount of TNF-awas also significantly reduced
compared toNSsham(P=0.046),whilenosignificantdifferencewas
found between sham and NS sham animals.
Analysis of peripheral circulating leukocytes showed LPS-
induced dynamic changes in total WBC (Figure 4C), neutrophilsA B C D
E F G H
FIGURE 4 | Chronic SpN Neuromodulation Evokes Anti-Inflammatory Effects During LPS-Induced Endotoxemia. (A) Graphs showing TNF-a concentration
quantified in the peripheral plasma collected at different time points after i.v. injection of 0.025 µg/kg of LPS. The data are shown for non-surgical (NS) sham (grey),
sham (black) and SpNS (red) animals. (B) Graph showing the quantification of the relevant TNF-a AUC (between 0.5-2 h post LPS) derived from (A). Data are shown
and were analyzed using the expressed as Log10 normalized AUC values. The single data points with mean are shown (C, D) Graphs showing total white blood cell
(C) or monocyte (D) cell counts from peripheral blood between 0 and 24 h post LPS injection. (E, F) Quantification of peripheral blood monocytes stained with
antibodies against CD16 (E) or CD172a (F) over time. (G) Representative histograms showing the changes over time of CD14 expression on CD16+ monocytes in a
sham and a SpNS representative pig. (H) Quantification of the median fluorescence intensity (MFI) of CD14 expression on CD16+ monocytes over time. (A, C–F, H)
Data are expressed as mean ± s.e.m. (E, F, H) Data are expressed as relative change over the baseline (value prior to LPS injection). (A, B) n = 6 for SpNS; n = 5
for sham. (C–E) n = 6 for SpNS; n = 5 for sham. (E, F, H) n = 3 for SpNS; n = 4 for sham. The sham group is shown in black and SpNS group in red. *P ≤ 0.05; **P
≤ 0.01; ***P ≤ 0.001 vs Sham or NS Sham.March 2021 | Volume 12 | Article 649786
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lymphocytes (Supplementary Figures S7F–H). In all animals
there was a significant effect of time in all the four parameters
(P<0.0001 for all). Total circulating WBCs showed an initial
leukopenia, followed by leukocytosis. There was approximately a
40% reduction from baseline values of WBCs which reached a
minimum around 1 h, followed by an elevation at 4 h (130-160% of
baseline) which resolved to baseline values by 24 h (Figure 4C).
These changes were mainly driven by variation in neutrophil
number (Supplementary Figure S7A). Additionally, monocytes
showed an initial reduction, with a minimum around 1.5 h, which
then resolved by 24 h (Figure 4D). When comparing SpNS and
sham animals, there was a significant effect of neuromodulation on
the number ofmonocytes at 3 and 4 h post-LPS (overall ANCOVA
P=0.021; post-hoc analysis P=0.004 andP=0.009 respectively), with
a higher proportion of circulating monocytes in SpNS animals
versus sham. There was no significant effect of SpNS on WBCs or
neutrophils. Furthermore, there were no changes in blood
biochemistry parameters following LPS administration in either
SpNS or sham animals. All hematological and clinical biochemistry
data can be found in Supplementary Table S2.
Flow cytometry analysis also revealed an effect of LPS
administration on the proportion of peripheral leukocyte subsets
at 3 h post LPS, before returning toward baseline levels at 24 h (in
line with hematological analysis). There was however a significantly
smaller LPS-induced reduction in circulating monocytes in SpNS
animals, quantified as CD16+ monocytes (P=0.039), with post-hoc
analysis revealing a significant effect at the 3 h timepoint (P=0.031;
Figures 4E and S7B). Analysis of CD172a+ monocytes revealed no
overall significant effect of SpNS (P=0.065), however post-hoc
analysis revealed a significantly smaller LPS-induced reduction at
the 3 h timepoint in stimulated animals (P=0.029; Figure 4F and
S7C). Smaller changes from baseline in stimulated animals were
also seen for CD14+ monocytes and CD163+ monocytes (Figures
S7D–E). Additionally, when assessing the expression of CD14 on
CD16+ monocytes, stimulated animals presented with a reduced
CD14 expression (MFI) level (Figures 4G, H; overall ANCOVA
P=0.047; post-hoc analysis P=0.040 at the 3 h timepoint); no
difference was observed for CD16+CD14low. No statistically
significant differences between groups were observed for CD4+
and CD8+ lymphocytes (Supplementary Figure S7F–G).
Effects of Chronic Neuromodulation on Specialized
Pro-resolving Mediators
In order to understand if SpN neuromodulation could affect
inflammation resolution processes, further than modulating
cytokine production, the concentration of SPMs in peripheral
plasma was quantified using LC-MS/MS-based lipid mediator
profiling. Lipid mediators from all four major essential fatty acid
metabolomes were identified, including the docosahexaenoic acid
andn-3docosapentaenoic acidmetabolomes (SupplementaryTable
S3). These mediators were detected in accordance with published
criteria that include matching retention time and at least six
diagnostic ions in the MS/MS spectrum (26). Assessment of
plasma mediator concentrations using partial least square
discriminant analysis (PLS-DA) demonstrated that chronic SpNFrontiers in Immunology | www.frontiersin.org 11neuromodulation led to a shift in plasma lipid mediator profile.
This was highlighted by a shift in the cluster of lipid mediators
representing plasma collected from pigs subjected to chronic
neuromodulation when compared with sham animals (Figures
5A–D). Of note, this shift in plasma lipid mediator profiles was
present at 8 days after initiation of chronic neuromodulation (Figure
5A), prior to LPS administration, and was retained throughout the
24 h time course of LPS challenge (Figures 5B–D). In order to
evaluate the lipid mediators that contributed to this separation
between the two experimental groups, the variable in importance
(VIP) score was assessed; this determines the contribution of each
mediator to the observed group separation. Several pro-
inflammatory eicosanoids including PGD2 and PGE2, as well as
SPMs from the protectin and resolvin bioactive metabolomes, were
among those that contributed to the separation between SpNS and
sham animals (Figures 5A–D; right panels). Of note, concentrations
of the inflammatory eicosanoids were decreased in the stimulated
group, whereas SPM concentrations were increased (Figures 5A–D;
and Supplementary Table S3).
Lipid mediator pathway analysis was conducted by assessing
the flux down each of the four bioactive metabolomes,
comparing between SpNS and sham pigs at 24 h post LPS. An
upregulation of several ALOX15-derived mediators, including
the DHA-derived RvD1, RvD2, PD1, the n-3 DPA derived
RvD5n-3 DPA, the EPA-derived RvE1, RvE2, RvE3 and the AA-
derived LXB4, was observed in SpNS pigs compared to sham
(Figure 5E). Interestingly, upregulation of the ALOX-15
pathway was also observed prior to LPS administration (8 days
after initiation of chronic neuromodulation) characterized by
increased levels of family D and E resolvins (RvD1, RvD5 and
RvE1, RvE3) and LXB4 (Supplementary Figure S8).
Finally, to determine whether SpNS stimulation directly regulates
plasma lipid mediator profiles, rather than as a downstream
consequence of chronic stimulation, the impact of acute SpNS on
plasma SPMconcentrationswas investigated using samples collected
from experiments previously performed under terminal anesthesia
(4). In line with chronic stimulation experiments, the lipid mediator
profiles from acutely SpN stimulated pigs (stimulation applied
continuously from -2 to +1 h relative to LPS administration)
clustered separately from those obtained from sham animals when
using PLS-DA across 2 h time window after LPS administration
(Supplementary Figure S9). Assessment of VIP scores
demonstrated that acute SpNS downregulated plasma
prostaglandin concentrations, and upregulated resolvin and
protectin concentration (Supplementary Figures S9A–C; right
panels; and Supplementary Table S4). Similarly to chronically
stimulated pigs, acute stimulation promoted SPM profile
separation prior to LPS injection (2 hours after initiation of
stimulation) mainly via upregulation of a number of ALOX15-
derived SPMs (including RvD3 and RvE3) at both 0 h
(Supplementary Figure S10) and 2 h (Supplementary Figure
S11) after LPS injection.
Terminal Assessment of Electrode-to-Nerve Integrity
Following in vivo LPS assessment, animals were terminally
anesthetized between 40- and 70-days post-implantation andMarch 2021 | Volume 12 | Article 649786
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electrode around the splenic NVB and to confirm continued SpN
function through stimulation-mediated target engagement
(increase in SpA BF and mABP) and subsequent post-mortem
histological examination.
Contrast angiography of the SpA demonstrated that all the
e lectrodes were reta ined around the splenic NVB
(Supplementary Figure S12A). Successively the animals were
instrumented to perform electrophysiological recordings. To
evaluate the functionality of the nerve-to-spleen circuit,Frontiers in Immunology | www.frontiersin.org 12multiple SpN stimulations were performed while recording
evoked changes in systemic mABP, SpA BF and eCAP.
eCAP generation, confirming the integrity of the cuff electrode-to-
nerve interface, was demonstrated in all animals in recordings made
distally to the cuff electrode (Supplementary Figure S12B).
Stimulation of the SpN (at the amplitude delivered during conscious
phase)witha10Hzcontinuousparadigmfor60sevokedan increase in
mABPof 3.20±2.51%andadecrease in SpABFof -5.68±3.50%at 15
µC (n=5;Figures 6B,D). At 40 µC (Figures 6B,D) changes inmABP





FIGURE 5 | Chronic SpN Neuromodulation reprograms peripheral blood lipid mediator profiles. Porcine splenic nerve was stimulated chronically for 8 days. Plasma
was collected immediately prior to LPS challenge (A), 0.5 (B), 3 (C) and 24 (D) h post LPS challenge and lipid mediators were investigated using LC-MS/MS-based
profiling. Results were interrogated using Partial Least Square Discriminant Analysis. (Left panels) Display Score Plots. Colored area represents the 95% interval
confidence. (Right panels) Plots displaying the lipid mediators with the 10 highest VIP scores from component 1. n = 5 for Sham group and n = 6 for SpNS group.
(E) Flux down each of the bioactive metabolomes was assessed in the samples collected 24h post LPS injection. Pathway analysis for the differential expression of
mediators from the DHA and n-3 DPA (left panel) and EPA and AA (right panel) bioactive metabolomes in SpNS group when compared to Sham group. Results are
expressed as the fold change. Green boxes indicate the SPMs upregulated in the SpNS group at 24h post LPS (vs Sham). n = 5 for Sham group and n = 6 for
SpNS group.March 2021 | Volume 12 | Article 649786
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an external pulse generator up to 40 µC using a 1 or 2ms pulse width
(Figures 6A, C). At 40 µC, a similar magnitude in response was
observed in both groups of animals with an increase in mABP (1 ms:
9.10±4.07%;2ms: 9.98±4.41%)ordecrease inSpABF(1ms: -62.15±
25.41; 2 ms: 53.84 ± 10.15%).
Considering change in mABP or SpA BF at termination as an
indication of nerve engagement during the conscious phase of the
study, Supplementary Figures S12C–D show the correlation
between these measurements and the TNF-a AUC0.5-2.0.
Comparing across all animals, there was no apparent correlation
between the degree of nerve engagement (as assessed by change in
mABP or SpA BF) and the overall TNF-a AUC (r2 = 0.04 or
0.17 respectively).Frontiers in Immunology | www.frontiersin.org 13Finally, all animals were heparinized and then euthanized. Gross
pathological and histopathological examinations were then
performed. No gross pathological abnormalities were noted in
any animal. Histopathological analysis demonstrated that leads
were well-tolerated, with no changes observed in SpA or vein. In
some animals, changes in nerve fascicles restricted to Schwann cell
hyperplasia and perineurial fibrosis with occasional fascicles
showing evidence of intra-fascicular edema were observed.
Representative histological sections from two SpNS animals show
minimal or low severity (Figures 6E, F, respectively) response to
chronic cuff implantation around the splenic NVB and stimulation,
further confirming the integrity of the functional neural
connections. Furthermore, no device-related abnormalities were
observed in tissue sections from the spleen, pancreas or liver.A
E F
B C D
FIGURE 6 | Physiological and Histological Assessment Confirms Integrity of Electrode-Nerve-Spleen Circuitry at Termination. (A, C) Percentage changes
(normalized to pre-stimulation baseline) in mABP (A) and SpA BF (C) obtained when stimulating the SpN with the implanted cuff at different intensities, using an
external stimulator, up to 40 mC. The curves obtained with two different pulse widths (1 and 2 ms) are shown. (B, D) Graphs showing the maximum percentage
changes in mABP and SpA BF achieved at termination at relevant IPG output (15 or 40 mC), delivered at 10 Hz continuously for 60 s. Data in A-D are shown as
mean ± s.e.m. (E) Low power image of transverse section from the splenic artery from a representative animal. The SpA is surrounded by numerous fascicles with
normal morphology. The white band encircling the artery and fascicles represents the former location of the implanted cuff. The black box highlights the region
represented in (E-e; higher power image) and shows nerve fascicles with normal morphology. A band of mature fibrotic tissue is part of the fibrotic capsule
surrounding the implant and represents an expected and acceptable response to the device. (F) Low power image of a transverse section from the splenic artery
from a second representative animal. A more significant tissue response to the presence of the implanted cuff is observed here when compared to that seen in (E).
The SpA is surrounded by numerous fascicles. The white band surrounding segments of the artery and fascicles represents the former location of the implanted cuff.
The black box highlights the region represented in (F-f; higher power image) and shows nerve fascicles with evidence of increased cellularity (Schwann cell
hyperplasia) and perineural fibrosis and represents a localized chronic response to low level nerve injury. * = Nerve fascicle; # = mature band of fibrotic tissue,
X = former location of implanted cuff, SpV, splenic vein.March 2021 | Volume 12 | Article 649786
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The results presented here using a large-animal model provide: i)
a novel preclinical surgical procedure to implant a SpN
circumferential cuff electrode and IPG; ii) a refinement of SpN
stimulation parameters for efficacy and target engagement; and
iii) a robust demonstration of the immunomodulatory effects of
SpN neuromodulation (induction of pro-resolutive SPMs,
suppression of LPS-induced TNF-a levels, and monocyte
mobilization and activation).
Immunomodulatory effects were achieved utilizing refined
stimulation parameters that were well tolerated by the animals
(up to 40 µC) and did not affect nerve integrity (assessed between
40 and 70 days post-implantation), as demonstrated by terminal
electrophysiology, physiology and histology. These are
fundamental requirements of bioelectronic medicines. Ideal
stimulation parameters, in fact, should be able to i) maintain
nerve engagement over t ime, i i ) produce efficient
neurotransmitter release, iii) cause minimal/no off-target
effects, iv) cause no/minimal axonal and tissue damage, while
iv) maintaining treatment efficacy. Ideally, this should be
demonstrated in an animal model sized to best match the
anatomy and physiology of the human patient (20, 28).
Recently we have shown that for splenic neuro-immune
modulation the pig represents such a human-relevant and
functional model (4).
Across species, the SpN consists mainly of unmyelinated
axons (4, 29), which represent a particular challenge in the
field of neuromodulation. Achieving and maintaining optimal
unmyelinated nerve engagement is a difficult requirement due to
the higher activation thresholds (30) when compared to
myelinated nerves. Uniform activation of the SpN is further
challenging due to the structure of the splenic NVB composed of
an artery, associated adipose tissue, and dispersed fascicles (31,
32). When stimulating at 1 Hz, conduction velocity was in line
with previous data for unmyelinated axons (4) and e.g (27).
Stimulation of the SpN at continuous frequencies higher than
1 Hz (specifically 10 and 30 Hz) caused an increase in eCAP
latency as well as a reduction in eCAP amplitude, suggesting a
reduction in axonal recruitment and as a result, less efficient
nerve activation over successive stimulation pulses. This is again
in line with that previously described for other unmyelinated
axons. Stimulation of sensory nerves, for example, is known to
cause “action potential conduction slowing” (27, 33) where
repetitive stimulations cause progressive reduction of
conduction velocity (as evidenced by an increase in latency)
and increase in activation threshold (27). Therefore, low
frequency stimulation may be used to efficiently stimulate the
SpN. However, stimulation at higher frequencies also allows the
delivery of larger amounts of neurotransmitter (i.e. NA) within a
certain time frame, potentially producing a more robust
immunomodulatory effect. Interestingly, when the SpN was
stimulated continuously at 10 Hz, during the initial period
(~10 pulses) an augmentative effect was observed on eCAP
recordings (increase in eCAP amplitude and conduction
velocity) followed by subsequent slowing and reduction of theFrontiers in Immunology | www.frontiersin.org 14eCAP. The former effect, named “action potential conduction
speeding” has also previously been observed in unmyelinated
sensory nerves (34). Together these suggest that highly efficient
stimulation can be achieved at frequencies higher than 1 Hz,
providing that a short “on” period is used. This is in line with our
data showing that 10 Hz burst (i.e. 0.5 s on; 4.5 s off) provided
efficient nerve recruitment (increase in eCAP amplitude and no
conduction slowing) and a more efficient release of NA (when
normalized to the total number of pulses delivered in the same
time window). This theoretically translates into a more energy-
efficient clinical therapy; with reduced total stimulation on-time
of the neuromodulation device. Additionally, and perhaps more
importantly, stimulation with the 10 Hz burst paradigm also
reduced physiological effects on mABP and SpA BF, when
compared to continuous 10 Hz (or higher) stimulation, to
levels comparable to those caused by low frequency
(1 Hz) stimulation.
While continuous stimulation at 10 Hz (or higher) is not
preferred for long-term chronic use, due to the local and systemic
cardiovascular effects, it still provides a useful paradigm for
intraoperative assessment of nerve target engagement (4).
SpNS-induced increase in systemic blood pressure seen in the
pig is due to smooth muscle-mediated splenic contraction, with
consequent release of stored blood and vasoactive factors (4, 35).
The magnitude of this phenomenon in man is currently unclear
since reports on splenic contractions are sparse and discordant
(36, 37). Changes in SpA BF induced by activation of SpN
represent a potential acute biomarker that is currently under
investigation in human clinical trials (clinicaltrials.gov Identifier:
NCT04171011). However, minimizing the impact of any chronic
neuromodulation therapy on the cardiovascular system is
desirable for long-term human use. The use of the burst
stimulation paradigm will allow the clinical investigation of the
efficacy of long-term SpN neuromodulation, in the presence of
reduced effects on the cardiovascular system, whilst maintaining
nerve activation and neurotransmitter release in the spleen.
Importantly for translation to human use, stimulation of the
SpN resulted in no observable sensation in conscious animals.
Using the burst stimulation parameters there was no evidence of
behavioral changes during SpN neuromodulation up to 40 µC.
This is in line with other work showing that only a small
proportion (<5%) of SpN axons in pigs and humans are
afferent in phenotype, based on calcitonin gene-related peptide
staining (4, 31). Furthermore, literature evidence of splenic
afferent fibers has described roles only associated with
mechanical and pressure sensing (38). Together these findings
suggest that SpN neuromodulation may be equally well tolerated
in man, but it remains to be confirmed in future clinical trials.
Based on the NA output measured during acute terminally-
anesthetized experiments we hypothesized that a five-minute
stimulation with the 10 Hz burst paradigm would induce
immunomodulatory effects. Stimulation of the SpN in
conscious pigs showed a clear suppression of peripheral TNF-
a in the systemic circulation following systemic LPS-challenge,
in line with the results obtained in similar models used in
anesthetized mice, rats and pigs (2, 4, 8). In this study,March 2021 | Volume 12 | Article 649786
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reduction as compared to that previously observed by our
group in pigs under terminal anesthesia (ca. 20-30%) (4). This
could reflect either an unmasked effect of stimulation in a setting
devoid of anesthetic agents, known to affect the nervous and
immune system, or a cumulative immunomodulatory effect due
to the delivery of multiple stimulations over several days when
compared to acute stimulation.
The immunomodulatory effect of splenic nerve stimulation is
most likely caused by activation of efferent nerve fibers, rather
than a reduction in SpA BF. The previous study by Donegà et al.
(4) compared SpNS versus left vagus nerve stimulation (LVNS;
included as a positive control) versus sham (mechanical partial
occlusion of the splenic artery resulting in a 50% reduction in
blood flow) in a terminally-anaesthetized LPS-challenge model
in pigs. There was a significant inhibitory effect of SpNS or LVNS
on hypotension, tachycardia and ultimately survival. However
there was no effect of mechanical occlusion of the splenic artery
in sham animals. Additionally it was demonstrated that NA is
able to suppress TNF-a release in vitro in pig splenocyte cultures.
The terminal physiological measures allowed us to estimate the
degree of SpN activation evoked in the animals during the chronic
therapeutic stimulation. Using the previously described correlation
between SpA BF changes and SpN activation (4), we estimated that
the therapeutic stimulation intensity delivered throughout conscious
chronic neuromodulation evoked up to 60% nerve activation across
all animals tested. Interestingly, there was no apparent evidence of
correlation between the magnitude of SpA BF response measured at
termination (as a surrogate indication of the degree of nerve
engagement throughout the study) and the magnitude of the
immunomodulatory effect (based on TNF-a AUC0.5-2.0). A similar
activation level led to cytokine suppression in our previous terminal
studies (4), suggesting that immunomodulatory activity in response
to exogenously-applied LPS can be achieved without requiring 100%
nerve activation. Clinical studies will help determine the clinical
translation of this phenomenon in patients with acute and/or
chronic inflammatory disorders. Although this observation may
vary among different inflammatory conditions, it represents an
important precedent in the case that tolerability to nerve activation
(however unlikely) would limit the amplitude of each individual
stimulation in certain patients.
The data presented here also extend our understanding of the
immunomodulatory effect induced by SpN neuromodulation,
beyond regulation of cytokine production. Modulation of TNF-a
production by SpN stimulation was associated with a different
response in peripheral monocytes when compared to sham
animals. Endotoxin administration is known to cause
recruitment of peripheral leukocytes into marginal pools, with
consequent reduction of circulating levels (39), as observed here.
However, SpN stimulated animals showed a less pronounced
change in peripheral monocytes following LPS injection, as
measured by hematology and flow cytometry. In particular,
CD163+ and CD172a+ monocytes were more strongly reduced
in sham animals at 3 h post-LPS. These populations in the pig are
the closest representation of the human (CD14dimCD16+) and
mouse (CX3CR1highGr1-CCR2) “non-classical monocytes” (40–Frontiers in Immunology | www.frontiersin.org 1542). These monocytes have been shown in mice to patrol blood
vessels and rapidly infiltrate tissues during inflammation where
they produce cytokines and chemokines (43), and have been
associated with resolution functions (44). In parallel we also
observed a reduced accumulation of CD16+CD14high monocytes
in stimulated animals, which in pigs represent the population of
“classical monocytes” , characterized in humans by
CD14highCD16- and in mice by CX3CR1lowGr1+CCR2+ (40,
43, 45, 46). These monocytes are known instead to be slowly
activated in response to inflammatory stimuli and then infiltrate
inflamed tissues and produce pro-inflammatory mediators (43).
Taken together these data suggest that SpNS reduces the
monocyte response to LPS, resulting in a reduction of classical
pro-inflammatory monocyte peripheral accumulation
(CD16+CD14high) and an increased (compare to sham)
proportion of non-classical, pro-resolving monocytes (CD163+,
CD172a+). This effect could be directly mediated by SpNS,
possibly affecting monocyte-endothelium interactions and cell
recruitment, or as a cascade consequence of the modulation of
cytokine (and other mediators) production.
In addition to reducing classical pro-inflammatory responses,
SpN neuromodulation led to the peripheral accumulation of
specialized pro-resolutive lipid mediators able to influence
leukocyte responses. Recent literature suggests that vagal
connections to abdominal organs may be key in regulating
resolution mechanisms (23, 24). For the first time we show
that the SpN may be part of this circuitry and that acute and
chronic stimulation can modulate SPM production. The
observed upregulation of ALOX15-derived SPMs in stimulated
animals suggests that the splenic nerve may be regulating specific
mechanisms in resolution processes.
The endotoxemia model used here is known to activate
immunological pathways characteristics of many inflammatory
diseases and therefore we infer SpN neuromodulation may have
beneficial effects in inflammatory conditions, in particular where
monocytes and splenic leukocytes play a crucial role in the
pathogenesis and maintenance of disease activity. In addition,
pro-resolving SPMs are known to play a crucial role in pre-
clinical models and patients with acute and chronic
inflammatory conditions, such as RA, atherosclerosis and
myocardial infarction. For example, some of the ALOX-15
derived SPMs specifically regulated by SpNS, like RvD3 and
RvD1, have been shown to have therapeutic effect in arthritis
models and to be produced by macrophages abundant in drug-
free remission patients (47, 48); RvD2 and MaR1 prevent
atheroprogression in mice (49); RvD1 produced by spleen-
derived leukocytes drives resolution in the heart after
infarction (50). In line with the above, early evidence exists
that modulating SpN activity in mice with arthritis can reduce
disease activity (10).
While the SpN stimulation directly targets the spleen, it is of
note that changes were observed in the systemic circulation.
Specifically, both acute or chronic stimulation were able to
modulate the expression of SPMs, with most changes
associated with ALOX15-derived metabolites, in either naïve or
endotoxemic states. These findings suggest that the ALOX15March 2021 | Volume 12 | Article 649786
Sokal et al. Splenic Nerve Neuromodulation Promotes Resolutionpathway is specifically activated by SpN neuromodulation. It is
currently unknown if this effect in driven directly within the
spleen. For example, outflow of NA and other factors from the
spleen may potentially cause downstream effects on peripheral
cells and other organs. However, it is known that NA secreted
from the spleen into peripheral circulation is rapidly removed by
circulating metabolizing enzymes and should have very little
effect on other organs/cells. Indeed, in a previous study following
SpN neuromodulation, we observed an increase in plasma NA
only in blood sampled locally from the splenic vein and not from
the systemic circulation (4). In addition, during 7-days of
stimulation no changes in non-classical CD163+ or CD172a+
monocytes were observed. Non-classical monocytes have been
shown to be mobilized from peripheral pools by systemic
catecholamine release (51). Therefore, although some NA exits
the spleen parenchyma, the concentration is unlikely to be
sufficient to cause systemic effects. Clinical trials will examine
the magnitude of effect of SpN neuromodulation on these
pathway-specific mediators and their utility as a measure of
target engagement. While SpA BF can be used intraoperatively,
defining a chronic conscious peripheral biomarker of SpN
activation of immunological pathways within the spleen would
allow the clinician to optimally adjust stimulation parameters to
maximize therapeutic effect while minimizing off-target effects.
Importantly, prior to LPS challenge we did not observe
systemic immune suppression, as assessed by ex vivo TNF-a
assays, peripheral blood hematology and flow cytometry. This
strengthens our original observations in acutely-stimulated
animals where no changes in peripheral white blood cells were
observed following SpNS (or VN stimulation), as opposed to the
leukopenia induced by pharmacological treatment with
dexamethasone (4). Thus, we propose that SpN stimulation,
rather than globally suppressing the immune system, is able to
prime it toward a more balanced and pro-resolutive phenotype
that translates into reduced inflammatory responses upon
endotoxin challenge.
This study also investigated the outcomes of chronic
implantation of a circumferential cuff electrode around the
splenic NVB and any effects of chronic neuromodulation by
such a device. The laparoscopic surgical implantation procedure
was developed through collaborative work between veterinary
and human surgeons and stimulation electrode implantation was
designed to be clinically translational between pigs and humans.
Terminal contrast angiography revealed that all stimulating
electrodes were retained around the splenic NVB.
Confirmation of nerve function was performed at termination
through eCAP recordings, assessment of physiological effects of
stimulation and histological assessment of nerve health.
Stimulation at termination continued to evoke an increase in
mABP and decrease in SpA BF, similar to that seen on
implantation. It was possible to record eCAPs distally to the
implanted stimulation electrode. While not an indication of
nerve function of the whole splenic NVB, successful recordings
of eCAPs from a randomly selected nerve fascicle do suggest that
function is maintained. Finally, histopathological analysis
demonstrated that stimulation electrodes were well-toleratedFrontiers in Immunology | www.frontiersin.org 16with minimal or low severity changes in nerves. Changes in
fascicles were restricted to Schwann cell hyperplasia and
perineurial fibrosis with occasional fascicles showing evidence
of intra-fascicular edema, which are unlikely to affect nerve
function indicating that the system is well-tolerated.
In summary this work demonstrates that chronic conscious
splenic neuromodulation can be achieved by implanting
electrodes around the splenic NVB in a minimally-invasive
manner and can safely deliver highly tolerable selective
activation of splenic immunomodulatory circuits. Such SpN
neuromodulation primes the immune system toward a pro-
resolutive phenotype such that following systemic immune
challenge, there is a pronounced, effective and balanced anti-
inflammatory effect. This preliminary study performed
exclusively in female pigs represents a significant advancement
toward a better understanding of neuro-immune modulatory
mechanisms in large animal species, as well as toward the
development of a novel bioelectronic medicine for patients
with acute or chronic inflammatory conditions targeting the
near-organ autonomic nervous system of the spleen. Together
these findings support the use of chronic neuromodulation of the
SpN in human clinical trials to investigate the effects of SpN
neuromodulation for the treatment of inflammatory disorders.DATA AVAILABILITY STATEMENT
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